The first authorized generic version of Azopt® 1% (brinzolamide ophthalmic suspension) has been made available by Teva Pharmaceuticals USA, Inc.
Brinzolamide ophthalmic suspension 1%, a carbonic anhydrase inhibitor, is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Following topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure.
Brinzolamide ophthalmic suspension 1% may be used concomitantly with other topical ophthalmic agents to lower intraocular pressure. The drugs should be administered at least 10 minutes apart if more than 1 topical ophthalmic drug is used.
The most common adverse reactions associated with treatment include blurred vision and bitter, sour or unusual taste.
The product is supplied in 10mL and 15mL bottles containing 10mg/mL of brinzolamide.
Teva announces launch of first generic version of Azopt® (brinzolamide ophthalmic suspension) 1%, used to treat high pressure inside the eye, in the United States. [press release]. Tel Aviv, Israel and Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; March 8, 2021.